The PROQURE project aims to provide prostate cancer patients with more cure and better
quality of life. The first part of this project (PROQURE-1) aims to explore an innovative
combined modality treatment strategy for patients with node-positive prostate cancer (N1M0).
The current standard of care for these patients, external beam radiotherapy (EBRT) of the
prostate and regional pelvic nodes combined with 2-3 years androgen deprivation therapy
(ADT), leads to suboptimal tumor control while inducing significant and potentially
persistent toxicity. To overcome this, the current locoregional treatment is complemented
with systemic Lutetium-177-PSMA radioligand therapy in a phase I study, with the aim to
achieve better tumor control while potentially reducing or obviating ADT and its associated
toxicity for future patients.